期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 339, 期 1-2, 页码 223-225出版社
ELSEVIER
DOI: 10.1016/j.jns.2014.01.035
关键词
Devic's disease; Neuromyelitis optica; NMO; AQP4; Aquaporin-4; Natalizumab
资金
- NHS National Specialised Commissioning Group for Neuromyelitis Optica
- NIHR Oxford Biomedical Research Centre
- Novartis
- Merk Serono
- TEVA
- Biogen
- Bayer Schering
- Bayer-Schering
- Biogen-Idec
- Merck-Serono
Natalizumab, an effective treatment for MS, has been shown to exacerbate neuromyelitis optica (NMO) with aquaporin-4 antibodies, but whether this is the case in antibody negative NMO and atypical MS/NMO spectrum disorder overlap syndromes is unknown. We describe a patient with a relapsing optico-spinal demyelinating syndrome, negative for aquaporin-4 antibodies, who experienced a catastrophic brain relapse shortly after a single dose of natalizumab, highlighting that MS immunomodulatory drugs may worsen demyelination in patients with seronegative NMO and atypical MS/NMO overlap syndromes even if they are aquaporin-4 antibody negative. We summarise the treatments considered safe and effective in NMO, and those with potential to exacerbate disease. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据